Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.

CONCLUSIONS: Breast cancer patients treated with adjuvant trastuzumab in the HOP setting had a shorter duration of trastuzumab treatment and fewer trastuzumab infusions but incurred higher monthly total costs than patients treated in the POV setting. PMID: 24761820 [PubMed - in process]
Source: Journal of Managed Care Pharmacy - Category: Drugs & Pharmacology Tags: J Manag Care Pharm Source Type: research